PARP1
ENSG00000143799
Target class
Enzyme
Chromosome
1
Approved drugs
7
Clinical candidates (approved and in development)
13
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Target name
- PARP1
- Gene name
- Poly(ADP-ribose) polymerase 1
- Gene symbol
- PARP1
- Protein name
- Poly [ADP-ribose] polymerase 1 (PARP-1) (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 1) (ARTD1) (DNA ADP-ribosyltransferase PARP1) (EC 2.4.2.-) (NAD(+) ADP-ribosyltransferase 1) (ADPRT 1) (Poly[ADP-ribose] synthase 1) (Protein poly-ADP-ribosyltransferase PARP1) (EC 2.4.2.-) [Cleaved into: Poly [ADP-ribose] polymerase 1, processed C-terminus (Poly [ADP-ribose] polymerase 1, 89-kDa form); Poly [ADP-ribose] polymerase 1, processed N-terminus (NT-PARP-1) (Poly [ADP-ribose] polymerase 1, 24-kDa form) (Poly [ADP-ribose] polymerase 1, 28-kDa form)]
- PARP
- ARTD1
- Poly-PARP
- PARS
- PPOL
- ADPRT
- Gene biotype
- Protein coding
- Gene family
- Zinc fingers PARP-type|Poly(ADP-ribose) polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 173.97
- Tissue specificity (Gini)
- 0.244
- Tissue specificity (tau)
- 0.818
- KEGG gene identifiers
- hsa:142
- Protein interaction confidence
- 0.830551
- Protein interaction partners
- 158
- R-HSA-110362
- R-HSA-192814
- R-HSA-2173795
- R-HSA-3108214
- R-HSA-5685939
- R-HSA-5696394
- R-HSA-5696395
- R-HSA-5696400
- End position
- 226408154
- Start position
- 226360210
- Chromosome
- 1
- Strand
- Reverse
- Chromosome . Nucleus . Nucleus, nucleolus . Cytoplasm, cytosol . Note=Localizes to sites of DNA damage (PubMed:22683995, PubMed:23230272, PubMed:26344098, PubMed:27568560, PubMed:30675909, PubMed:32241924, PubMed:32358582, PubMed:34625544, PubMed:34795260). Recognizes (via PARP-type zinc-fingers) and binds DNA strand breaks (PubMed:22683995). Also binds normal/undamaged chromatin (PubMed:15607977). Auto poly-ADP-ribosylation promotes dissociation from chromatin (PubMed:15607977, PubMed:30675909, PubMed:32358582, PubMed:34625544). Extracted from chromatin by VCP/p97 following sumoylation and ubiquitination (PubMed:35013556). Translocates from the nucleus to the cytosol following phosphorylation by PRKDC (PubMed:35460603). Recruited to replication forks following interaction with CARM1 (PubMed:33412112). .
- SUBCELLULAR LOCATION: [Poly [ADP-ribose] polymerase 1, processed N-terminus]: Chromosome . Note=Following cleavage by caspase-3 (CASP3) and caspase-7 (CASP7) in response to apoptosis, this cleavage form irreversibly binds to DNA breaks. .
- SUBCELLULAR LOCATION: [Poly [ADP-ribose] polymerase 1, processed C-terminus]: Cytoplasm . Note=Following cleavage by caspase-3 (CASP3) and caspase-7 (CASP7) in response to apoptosis, translocates into the cytoplasm, where the auto-poly-ADP-ribosylated form serves as a poly-ADP-ribose carrier to induce AIFM1-mediated apoptosis. .
- Nuclear bodies
- Nucleoli
- Nucleoli fibrillar center
- Nucleoplasm
- PubMed 15607977
- PubMed 22683995
- PubMed 23230272
- PubMed 26344098
- PubMed 27568560
- PubMed 30675909
- PubMed 32241924
- PubMed 32358582
- PubMed 33412112
- PubMed 34625544
- PubMed 34795260
- PubMed 35013556
- PubMed 17177976
- PubMed 21799911
- PubMed 35460603
- PubMed 9518481
- PubMed 33168626
- PubMed 35104452
- PubMed 9721847
- Tissue specificity (tau)
- 0.818011
- Expression inequality (Gini)
- 0.244244
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 173.97
- Brain - Spinal cord (cervical c-1)
- 67.59
- Nerve - Tibial
- 59.23
- Spleen
- 57.1
- Cells - Cultured fibroblasts
- 54.22
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes173.97
- Brain - Spinal cord (cervical c-1)67.59
- Nerve - Tibial59.23
- Spleen57.1
- Cells - Cultured fibroblasts54.22
- Testis50.25
- Colon - Sigmoid47.29
- Pituitary46.38
- Brain - Cerebellar Hemisphere41.5
- Brain - Cerebellum39.88
- Bladder39.4
- Uterus39.06
- Esophagus - Muscularis36.97
- Cervix - Endocervix36.73
- Small Intestine - Terminal Ileum35.18
- Brain - Frontal Cortex (BA9)34.45
- Esophagus - Gastroesophageal Junction34.35
- Cervix - Ectocervix34.05
- Brain - Cortex33.19
- Brain - Substantia nigra33.14
- Prostate32.02
- Brain - Caudate (basal ganglia)31.37
- Ovary31.23
- Muscle - Skeletal30.9
- Vagina30.84
And 29 more, listed on the interactive page.
- GO:0000012
- GO:0000122
- GO:0000723
- GO:0006281
- GO:0006302
- GO:0006366
- GO:0006915
- GO:0006974
- GO:0007005
- GO:0030225
- GO:0030592
- GO:0032042
- GO:0032786
- GO:0032869
- GO:0032880
- GO:0034244
- GO:0034599
- GO:0034644
- GO:0036211
- GO:0043123
- GO:0043504
- GO:0045824
- GO:0045944
- GO:0070212
- GO:0070213
And 8 more, listed on the interactive page.
- GO:0000781
- GO:0000785
- GO:0001650
- GO:0005634
- GO:0005635
- GO:0005654
- GO:0005667
- GO:0005694
- GO:0005730
- GO:0005737
- GO:0005739
- GO:0005829
- GO:0016020
- GO:0016604
- GO:0032991
- GO:0032993
- GO:0035861
- GO:0043596
- GO:0090734
- GO:0003677
- GO:0003682
- GO:0003684
- GO:0003723
- GO:0003950
- GO:0005515
- GO:0008047
- GO:0008270
- GO:0019899
- GO:0019901
- GO:0031491
- GO:0042802
- GO:0042803
- GO:0044378
- GO:0061629
- GO:0140294
- GO:0140805
- GO:0140806
- GO:0140807
- GO:0140808
- GO:0140815
- GO:0140816
- GO:0140817
- GO:1990165
- GO:1990404
Related records
Trials (943)
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
- A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
- A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
- A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
- A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
- A Dye for the Detection of Cancer of the Tongue and Mouth
- A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
Drugs (14)
- 2X-121 Poly [ADP-ribose] polymerase-1 inhibitor
- Amelparib Poly [ADP-ribose] polymerase-1 inhibitor
- Amelparib dihydrochloride dihydrate Poly [ADP-ribose] polymerase-1 inhibitor
- E-7016 PARP 1, 2 and 3 inhibitor
- Niraparib Poly [ADP-ribose] polymerase-1 inhibitor
- Niraparib tosylate monohydrate Poly [ADP-ribose] polymerase-1 inhibitor
- Olaparib PARP 1, 2 and 3 inhibitor
- Pamiparib Poly [ADP-ribose] polymerase-1 inhibitor
- Rucaparib PARP 1, 2 and 3 inhibitor
- Rucaparib camsylate PARP 1, 2 and 3 inhibitor
- Senaparib Poly [ADP-ribose] polymerase-1 inhibitor
- Talazoparib Poly [ADP-ribose] polymerase-1 inhibitor
- Talazoparib tosylate Poly [ADP-ribose] polymerase-1 inhibitor
- Veliparib PARP 1, 2 and 3 inhibitor